Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH
NCT05362292Phase 4Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tolterodine, mirabegron in urinary incontinence (UI), overactive bladder (OAB), sponsored by University of California, San Francisco. Started Oct 2022; status: recruiting.
02
Drugs
tolterodinemirabegron
03
Conditions
urinary incontinence (UI)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05362292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362292.